AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis

Page created by Duane George
 
CONTINUE READING
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis - M... Page 1 of 11

AcuTect Scintigraphic Imaging for
Detection of Lower Limb Deep
Vein Thrombosis
Number: 0414

                                                                                Policy History
Policy
*Please see amendment for Pennsylvania                                             Last Review: 05/18/2021
Medicaid at the end of this CPB.                                                   Effective: 05/04/2000
                                                                                   Next Review: 04/21/2022
Aetna considers AcuTect scintigraphic imaging for detection
and localization of deep vein thrombosis (DVT) in the lower
extremity experimental and investigational because the clinical
value of this test in the management of persons with
suspected DVT has not been clearly established by the peer-
reviewed medical literature.

Background
Contrast venography (also known as contrast phlebography) is
the gold standard for the diagnosis of DVT, although it is rarely
used anymore because it is invasive, painful, time-consuming,
and entails exposure to significant amounts of radiation. For
patients with symptoms suggestive of DVT, compression
ultrasonography is the most frequently used test. Pooled
analyses showed that ultrasonography has a sensitivity of 96
% and a specificity of 98 % for proximal vein thrombosis. It
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 2 of 11

has been reported that venous thromboembolic complications
occur in less than 1 % of untreated patients in whom the
presence of DVT is rejected on the basis of serial
ultrasonography or ultrasonography plus either an assay for D-
dimer (a fragment that is specific for the degradation of fibrin)
or clinical score.

AcuTect (Diatide, Inc., Londenderry, NH) is a complex of a
small-molecule synthetic peptide, apcitide, and the
radionuclide, technetium (Tc) 99m (a gamma ray emitter).
Apcitide binds preferentially to glycoprotein IIb/IIIa receptors,
which are expressed on the surface of activated platelets, a
major component of active thrombus formation. Thus, it may
localize at sites where blood clots are present or forming.
AcuTect is approved for use in the scintigraphic imaging of
acute (not chronic) venous thrombosis in the lower extremities
of patients who have signs and symptoms of acute venous
thrombosis. It allows for early (10 to 60 minutes post-injection,
administered by injection into the antecubital vein) imaging of
DVT of the entire lower extremities, including the calf.

Information provided in the product labeling of AcuTect stated
that the agreement rates between AcuTect and contrast
venography are between 56 and 73 %. Furthermore, clinical
follow-up studies of patients with negative AcuTect scans have
not been carried out to determine if negative image findings
represent the absence of acute venous thrombosis, and the
rate of venous thromboembolic complications in untreated
patients after a negative AcuTect scan has not been
determined. Thus, the value of AcuTect in the management of
patients with suspected DVT has not been clearly established.

Dunzinger et al (2008) studied the detection of acute DVT in
patients presenting with clinical symptoms suggesting DVT
and pulmonary embolism (PE) with (99m)Tc-apcitide. A total
of 19 patients (11 males, 8 females) received within 24 hrs
after admission to the hospital a mean of 841 MBq (range
of 667 to 1,080) (99m)Tc-apcitide i.v. followed by planar
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 3 of 11

recordings 10, 60, and 120 mins after injection. Images were
compared to the results of compression ultrasonography
and/or phlebography. Patients with clinically suspected PE
underwent spiral computed tomography or lung perfusion
scans. (99m)Tc-apcitide scintigraphy showed acute clot
formation in 14 out of 16 patients where the other imaging
modalities suggested DVT. Positive scintigraphic results were
seen up to 17 days after the onset of clinical symptoms. In 3
out of 3 patients without any proof of DVT, (99m)Tc-apcitide
scintigraphy was truly negative. Glycoprotein receptor imaging
showed only one segmental PE in 6 patients with imaging-
proven sub-segmental (n = 3) or segmental PE (n = 3). The
authors concluded that (99m)Tc-apcitide scintigraphy may be
an easy and promising tool for the detection of acute clot
formation in patients with DVT up to 17 days after the onset of
clinical symptoms with a sensitivity of 87 % and a specificity of
100 %. However, it failed to demonstrate PE in 83 % of
examined patients with proven PE.

Tan et al (2009) noted that currently the combination of a
clinical decision rule, D-dimer testing and compression
ultrasonography has proved to be safe and effective for the
diagnosis of DVT in the lower extremities. Computed
tomography (CT) and magnetic resonance imaging (MRI) can
be useful as additional or secondary imaging modalities.
Somarouthu and colleagues (2010) discussed the approach
for diagnosing DVT in different patient populations. Clinical
features and probability assessment guide further diagnostic
tests. D-dimer testing is used as screening test; however,
duplex ultrasound remains the primary confirmatory test.
Furthermore, CT and MRI are used only in select patient
populations (e.g., when ultrasound results are equivocal, in
patients suspected of central venous DVT, or as a part of
combined protocol for diagnosis of PE). The authors stated
that contrast phlebography and plethysmography do not have
much of a role during routine diagnosis of DVT.
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 4 of 11

Contrast venography (phlebography) is the "gold-standard"
examination (Polak et al, 2005) for suspected deep venous
thromboses of the lower extremity. An iodine-containing
contrast agent is injected into a foot vein. DVT is present if a
distinct filling defect is present in a deep vein of the calf or
thigh. Other findings, such as an abrupt cutoff, absence of
filling or presence of collaterals, are less specific and may be
related to technical factors or to chronic venous thrombosis.
American College of Radiology Appropriateness Criteria
(Polak et al, 2005) on suspected lower extremity deep venous
thrombosis state that invasive contrast phlebography may be
necessary where other studies are equivocal or an intervention
is planned. Contrast phlebography is assigned an
appropriateness rating of 5 of 10. The authors note that,
although this examination serves as the "gold standard", it may
not give reliable results in 5 to 10 % of patients. It also carries
some risks: contrast reaction, local irritation or skin loss due to
extravasation, renal failure, and chemically induced
thrombophlebitis.

Guidelines on venous thromboembolism from the University of
Michigan (2009) state that phlebography "is seldom indicated
any longer". The guidelines state that phlebography carries
appreciable local morbidity, the risk of contrast administration,
and is technically inadequate in 7 to 20 % of studies.

Ultrasound is recommended for patients with intermediate to
high pretest probability of DVT in the lower extremities. Use of
ultrasound in diagnosing symptomatic thrombosis in the
proximal veins of the lower limb is recommended for patients
whose pretest probability of disease falls in the category of
intermediate to high risk of DVT under the Wells prediction
rule. Ultrasound is less sensitive in patients who have DVT
limited to the calf; therefore, a negative ultrasound does not
rule out DVT in these patients. Repeat ultrasound or
venography may be required for patients who have suspected
calf-vein DVT and a negative ultrasound and for patients who
have suspected proximal DVT and an ultrasound that is
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 5 of 11

technically inadequate or equivocal. Contrast venography is
still considered the definitive test to rule out the diagnosis of
DVT.

CPT Codes / HCPCS Codes / ICD-10 Codes

Information in the [brackets] below has been added for
clarification purposes. Codes requiring a 7th character are
represented by "+":

 Code         Code Description

 CPT codes not covered for indications listed in the CPB:

 78456        Acute venous thrombosis imaging, peptide

 Other CPT codes related to the CPB:

 75820        Venography, extremity, unilateral, radiological
              supervision and interpretation

 75822        Venography, extremity, bilateral, radiological
              supervision and interpretation

 78457        Venous thrombosis imaging, venogram;
              unilateral

 78458           bilateral

 ICD-10 codes not covered for indications listed in the CPB:

 I80.10 -     Phlebitis and thrombophlebitis of femoral vein
 I80.13

 I80.201 -    Phlebitis and thrombophlebitis of other and
 I80.9        unspecified deep vessels of lower extremities

 I82.0 -      Other venous embolism and thrombosis
 I82.91

 O22.00 -     Venous complications in pregnancy
 O22.93
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 6 of 11

 Code        Code Description

 O87.0 -     Venous complications in the puerperium
 O87.9

 Other HCPCS code related to the CPB:

 A9504       Technetium Tc-99m apcitide, diagnostic, per
             study dose, up to 20 millicuries

The above policy is based on the following
references:

 1. Birdwell B. Recent clinical trials in the diagnosis of
    deep-vein thrombosis. Curr Opin Hematol. 1999;6
    (5):275-279.
 2. Kraaijenhagen RA, Lensing AW, Wallis JW, et al.
    Diagnostic management of venous thromboembolism.
    Baillieres Clin Hematol. 1998;11(3):541-586.
 3. Lensing AW, Prandoni P, Prins MH, Buller HR. Deep-
    vein thrombosis. Lancet. 1999;353(9151):479-485.
 4. Kearon C, Julian JA, Newman TE, Ginsberg JS.
    Noninvasive diagnosis of deep vein thrombosis.
    McMaster Diagnostic Imaging Practice Guidelines
    Initiative. Ann Intern Med. 1998;128(8):663-677.
 5. Diatide Inc. AcuTect product insert. Londonderry, NH:
    Diatide; September 1998.
 6. U.S. Food and Drug Administration (FDA), Center for
    Drug Evaluation and Research. Summary minutes for
    the Medical Imaging Drug Advisory Committee
    Meeting. Silver Spring, MD, February 9, 1998.
 7. Taillefer R. Radiolabeled peptides in the detection of
    deep venous thrombosis. Semin Nucl Med. 2001;31
    (2):102-123.
 8. Institute for Clinical Systems Improvement (ICSI).
    Venous Thromboembolism. ICSI Health Care
    Guidelines. Bloomington, MN: ICSI; January 2002.
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M... Page 7 of 11

 9. Bates SM, Lister-James J, Julian JA, et al. Imaging
    characteristics of a novel technetium Tc 99m-labeled
    platelet glycoprotein IIb/IIIa receptor antagonist in
    patients with acute deep vein thrombosis or a history
    of deep vein thrombosis. Arch Intern Med. 2003;163
    (4):452-456.
10. Bernarducci MP. 'Pathophysiologic mapping' of venous
    thromboembolism: Opportunities for radiolabeled
    peptides. Q J Nucl Med. 2003;47(4):292-320.
11. McRae SJ, Ginsberg JS. The diagnostic evaluation of
    deep vein thrombosis. Am Heart Hosp J. 2004;2(4):205-
    210.
12. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet.
    2005;365(9465):1163-1174.
13. Ilahi OA, Reddy J, Ahmad I. Deep venous thrombosis
    after knee arthroscopy: A meta-analysis. Arthroscopy.
    2005;21(6):727-730.
14. Kearon C, Ginsberg JS, Douketis J, et al. A randomized
    trial of diagnostic strategies after normal proximal vein
    ultrasonography for suspected deep venous
    thrombosis: D-dimer testing compared with repeated
    ultrasonography. Ann Intern Med. 2005;142(7):490-
    496.
15. Polak JF, Yucel EK, Bettmann MA, et al.; Expert Panel on
    Cardiovascular Imaging. Suspected lower extremity
    deep vein thrombosis. ACR Appropriateness Criteria.
    Reston, VA: American College of Radiology (ACR); 2005.
16. Dunzinger A, Hafner F, Schaffler G, et al. 99mTc-
    apcitide scintigraphy in patients with clinically
    suspected deep venous thrombosis and pulmonary
    embolism. Eur J Nucl Med Mol Imaging. 2008;35
    (11):2082-2087.
17. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE,
    Tobolic T, Ireland B, Segal J, Bass E, Weiss KB, Green L,
    Owens DK, Joint American Academy of Family
    Physicians/American College of Physicians. Current
    diagnosis of venous thromboembolism in primary
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M...   Page 8 of 11

    care: A clinical practice guideline from the American
    Academy of Family Physicians and the American
    College of Physicians. Ann Fam Med 2007 Jan-Feb;5
    (1):57-62.
18. University of Michigan Health System. Venous
    thromboembolism (VTE). Guidelines for Clinical Care.
    Ann Arbor, MI: University of Michigan Health System;
    February 2009.
19. Tan M, van Rooden CJ, Westerbeek RE, Huisman MV.
    Diagnostic management of clinically suspected acute
    deep vein thrombosis. Br J Haematol. 2009;146(4):347-
    360.
20. Somarouthu B, Abbara S, Kalva SP. Diagnosing deep
    vein thrombosis. Postgrad Med. 2010;122(2):66-73.
21. Grant B. Diagnosis of suspected deep venous
    thrombosis of the lower extremity. UpToDate [online
    serial]. Waltham, MA: UpToDate; updated February 8,
    2010.
22. Institute for Clinical Systems Improvement (ICSI).
    Venous thromboembolism diagnosis and treatment.
    Bloomington, MN: Institute for Clinical Systems
    Improvement (ICSI); February 2009.
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M...   Page 9 of 11

Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan

benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial,
general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care

services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors

in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely
responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is

subject to change.

Copyright © 2001-2021 Aetna Inc.
AcuTect Scintigraphic Imaging for Detection of Lower Limb Deep Vein Thrombosis- M...   Page 10 of 11

AETNA BETTER HEALTH® OF PENNSYLVANIA

                              Amendment to
           Aetna Clinical Policy Bulletin Number: 0414 AcuTect
         Scintigraphic Imaging for Detection of Lower Limb Deep
                             Vein Thrombosis

There are no amendments for Medicaid.

                                                                                              annual 07/01/2021
You can also read